期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米联合地塞米松或化疗治疗多发性骨髓瘤10例 被引量：1

原文传递
导出
摘要 目的观察硼替佐米联合地塞米松或化疗治疗复发难治多发性骨髓瘤（MM）患者的疗效和不良反应。方法9例患者采用硼替佐米1．3mg／m^2，第1、4、8、11天，地塞米松20mg／m^2，第1、2、4、5、8、9、11、12天，沙利度胺100～200mg／d，第1天至第14天，其中1例85岁的老年患者使用硼替佐米加MP方案治疗，具体方案为：硼替佐米1．3mg／m^2，第1、4、8、11天，美法仑14mg／^2。，第1天至第4天，泼尼松60mg／m^2，第1天至第4天。结果中位随访9个月，其中3例患者接近完全缓解，6例患者部分缓解，1例患者轻微反应，病情稳定。最常见的不良反应为周围神经病变，10例中有4例，血小板减少2例，带状疱疹3例，胃肠道反应1例，乏力1例。均经对症治疗后缓解。结论对于复发难治的MM患者，硼替佐米联合地塞米松或化疗为一种安全有效的治疗手段。
作者 王丽昕
机构地区 山西省晋中市第一人民医院血液科
出处 《白血病．淋巴瘤》 CAS 2009年第9期563-564,共2页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 抗肿瘤联合化疗方案
分类号 R733.3 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed,refractory myeloma. N Engl J Med, 2003, 348: 2609-2617.
  • 2Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory, myeloma. Br J Haematol, 2004, 127: 165-172.
  • 3Richardson PG, Sonneveld P, Schuster MV, et al. For Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 2005, 352: 2487-2498.
  • 4Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 2006, 91: 1498- 1505.
  • 5Min CK, Lee MJ, Eom KS, et al. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. Jpn J Clin Oncol, 2007, 37: 961-968.

同被引文献9

  • 1Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of conbinatious of bortezomih, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 2012, 119: 4375-4382.
  • 2Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is snperior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietie stem cell transplantation in patients with newly diagnosed muhiple myeloma. Blood, 2012, 120: 9-19,.
  • 3Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with reeurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer, 2008, 113: 765-771.
  • 4Ghobrial 1M, Weller E, Vii R, et al, Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol, 20! l, 12: 263-272.
  • 5Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leakemia, 2006, 20: 1467-1473.
  • 6Fukushima T, lwao H, Sakai T, et al. Once weekly bortezomib plus dexamithasone therapy induced complete response,reducing severe gastrointestinal adverse invents for a palient with replased multiple myeloma-a case report. Gan To Kagaku Ryoho, 2012, 39: 805-807.
  • 7Reeder CB, Reece DE, Kukreti V, et al. Once- venus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 2010, 115: 3416-3417.
  • 8Fukushima T, Nakamura T, Iwao H, et al. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res, 2011, 31: 2297-2302.
  • 9钟玉萍,陈世伦.硼替佐米治疗复发难治性多发性骨髓瘤43例[J].白血病．淋巴瘤,2009,18(9):538-540. 被引量：6

引证文献1

二级引证文献2

白血病．淋巴瘤
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部